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Abstract
Background: The present study was carried out to evaluate cerebral perfusion in multiple sclerosis (MS) patients
with a moderate to severe stage of disease. Some patients underwent hyperbaric oxygen therapy (HBOT) and brain
perfusion between before and after that was compared.
Methods: We retrospectively reviewed 25 secondary progressive (SP)-MS patients from the hospital database.
Neurological disability evaluated by Expanded Disability Status Scale Score (EDSS). Brain perfusion was performed
by (99 m) Tc-labeled bicisate (ECD) brain SPECT and the data were compared using statistical parametric mapping
(SPM). In total, 16 patients underwent HBOT. Before HBOT and at the end of 20 sessions of oxygen treatment,
99mTc-ECD brain perfusion single photon emission computed tomography (SPECT) was performed again then
the results were evaluated and compared. Brain perfusion was performed by (99 m) Tc-labeled bicisate (ECD) brain
SPECT and the data were compared using statistical parametric mapping (SPM).
Results: A total of 25 SP-MS patients, 14 females (56 %) and 11 males (44 %) with a mean age of 38.92 ± 11.
28 years included in the study. The mean disease duration was 8.70 ± 5.30 years. Of the 25 patients, 2 (8 %) had
a normal SPECT and 23 (92 %) had abnormal brain perfusion SPECT studies. The study showed a significant
association between severity of perfusion impairment with disease duration and also with EDSS (P <0.05). There
was a significant improvement in pre- and post-treatment perfusion scans (P <0.05), but this did not demonstrate
a significant improvement in the clinical subjective and objective evaluation of patients (P >0.05).
Conclusions: This study depicted decreased cerebral perfusion in SP-MS patients with a moderate to severe
disability score and its association with clinical parameters. Because of its accessibility, rather low price, practical
ease, and being objective quantitative information, brain perfusion SPECT can be complementing to other
diagnostic modalities such as MRI and clinical examinations in disease surveillance and monitoring. The literature
on this important issue is extremely scarce, and follow up studies are required to assess these preliminary results.
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Background
Multiple sclerosis (MS) is an inflammatory demyelinating
disease of the central nervous system (CNS) that affects
myelin, oligodendrocytes, and axons, and eventually results
in neuronal loss and progressive neurologic disability [1].
In total, four disease courses have been distinguished:
relapsing remitting (RR), primary progressive (PP), sec-
ondary progressive (SP) and also progressive-relapsing
(PR) [2]. The RR type is constituted as the common
form of the disease. About two-thirds of patients with
RR-MS change in the SP phase where neurologic disabil-
ity has a progressive pattern between attacks [2, 3].
In the 1930s, Putnam explained the evidence of vascu-
lar occlusion in MS histopathology for the first time, and
believed that vascular occlusion and inflammation were
involved as antecedent processes in demyelinating dis-
ease evolution [4]. Wakefield et al. later reported similar
findings and showed fibrin deposition and vessel throm-
bosis without obvious cellular infiltration, which suggested
that the presentation of thrombosis in small veins and
capillaries supported the possible role of ischemic process
in MS disease [5].
Luke et al., who used single photon emission computed
tomography (SPECT), showed hypoperfusion of cerebral
blood flow (CBF) in the gray matter (GM) of the
frontal lobe of patients with progressive MS com-
pared with cerebral perfusion in control patients, al-
though the study reported normal perfusion in patients
with RR-MS [6]. Our previous study has similar results
and normal brain perfusion of MS patients in the early
stage and without significant disability [7]. In another
study, Brooks et al. showed that there was decreasing CBF
and oxygen utilization in both the white matter and the
cortical GM in the MS patients compared to the healthy
control group [8].
Some claims exist about the efficacy of HBOT in MS
patients. Fisher et al. [9–11], in a double-blind controlled
study, showed significant but transient improvements in
mobility, fatigability, and walking in MS patients receiving
HBOT. Warren et al., showed that HBOT resulted in an
augmentation of experimental allergic encephalomyelitis,
an animal model of MS [12]. Although different studies
had been carried out [13, 14], the assessment of such ther-
apy with functional modalities is scare in the literature.
What’s more, recent clinical trial researches along these
lines and provided evidence that HBOT can get better the
symptoms and life quality of in some neurological disor-
ders [15–25].
We aimed to evaluate cerebral perfusion in MS pa-
tients with a moderate to severe stage of disease. Be-
sides, we provided firm appraisal of the HBOT effect on
brain activity as assessed by SPECT imaging supplied by
quantitative methods and its possible correspondence on
clinical status of MS patients.
Methods
Participants and study design
We retrospectively reviewed 25 SP-MS patients from the
hospital database. The diagnosis was accomplished in
agreement with the “McDonald Criteria” [26]. Disability
was assessed by a single experienced neurologist blind to
the magnetic resonance imaging (MRI) findings using
the Expanded Disability Status Scale (EDSS) score [27].
Patients who had one new episode (within 1 month) of
acute otitis or those with chronic otitis (three episodes
or more within the previous year) were excluded, as were
those with any condition that put them at risk of
complications from HBOT (e.g. asthma, convulsions).
Patients with behavioral problems or those who had
had orthopedic surgery (within the prior 6 months),
or dorsal rhizotomy within the past 2 years, were also
excluded. Previous exposure to HBOT was also an exclu-
sion criterion.
Of these 25 patients, 16 met the criteria and would
undergo HBOT. In general, HBOT consisted of 100 %
oxygen at a pressure of 1.75 atm absolute (ATA) for
60 min. At the conclusion of 20 sessions of HBOT,
brain perfusion SPECT were performed again; the
results were evaluated and compared with previous
SPECT results.
This study was approved by the ethics committee of
the Bushehr University of Medical Sciences.
Imaging protocols
About one hour after an IV injection of 740 MBq
(20 mCi) 99mTc-ECD (AEOI, Tehran, Iran), the brain
SPECT was done. A SPECT equipped with a dual head
gamma camera (Siemens e-Cam, Germany), a pair of
low-energy and high-resolution collimators was done.
Projections were done in a 64 × 64 matrix at 64 steps,
30 s each step. Attenuation correction was done by the
Chang manner (attenuation coefficient 0.12 cm−1). The
projections were then processed using back projection
and Butterworth filter (Nyquist frequency cutoff = 0.5,
order = 5). Images were presented in three orthogonal
planes.
Image interpretation
Visual analysis
Brain SPECT studies were analyzed by two experienced
nuclear medicine specialists who were blind to the par-
ticipants’ data. Discrepancies in final impression were dis-
solved by consensus. The cortical and subcortical parts
were systematically evaluated. The abnormality in radio-
nuclide uptake was classified as follows: no decreased up-
take, or normal, mild diminished uptake, and moderate
and severe diminished uptake.
No focal hypoperfusion or observable asymmetry
in cortical or subcortical regions was considered as
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normal brain SPECT. Abnormal brain SPECT studies
were allocated to heterogeneous rCBF with focal hy-
poperfusion or visible asymmetry in at least two
slice series.
More particularly, the assessment was done separately
by two nuclear medicine practitioners who compared the
brain SPECT data and classified them as either: 1 = no
change, 2 = slight change and 3 = significant change. “No
change” was defined as no visual difference in the number
or size or severity of perfusion defects; “mild change” de-
fined to a diminish in number or size or severity of perfu-
sion defects; “noteworthy change” to a global perfusion
increase in addition to lessening of defect numbers or size
or severity.
Semi-quantitative analysis using statistical parametric
mapping (SPM)
At first, all the images were transformed to NIFTI format
using XMedCon software. After that for Normalization
step, all the images were spatially normalized to a standard
stereotactic space according to the Talairach and Tour-
noux atlas. Spatial normalization was performed using a
SPECT template (provided by SPM8) as a reference image.
Then, in smoothing step, all the images were smoothed
through using an isotropic Gaussian filter in order to get
better the signal to noise ratio.
After preprocessing steps mentioned above, each
patient image was compared on a voxel by voxel basis
with a pool of control group including 13 cases of non-
inflammatory non progressive CNS disorders with nor-
mal perfusion SPECT using T-test statistical analysis by
selecting two sample t-tests as a design, plus selecting
the healthy control group and each patient as the first
group scans and second group scan respectively. Relative
threshold masking was selected and its threshold was
left at the default value 0.8, so the mean intensity was
computed from those voxels with intensity higher than
0.8 of the entire scan average. Also, proportional scaling
global normalization with its default value (50 ml/dl/
min) was used to eliminate the differences between
global activities among individuals. It scales each image
separately such that its global brain activity will be speci-
fied value. Each individual scan was compared against
the reference control group which yields a contrast
T-map testing for regions with decreased activity (hy-
poperfusion) compared to the control group. Results
were obtained using (p <.05) corrected for multiple
comparisons (FWE: family wise error correction). Voxels
with a P value of less than 0.05 were considered to be
significantly different.
Finally, SPM image results then were displayed on a
three orthogonal brain which is called glass brain. The
regions with the most significant decreased perfusion
(CBF) obtained by SPM analysis were in agreement with
the regions specified by visual analysis of physician
blinded to the SPM results.
Statistical analysis
Continuous variables are presented as mean ± SD, and
categorical variables as the absolute values and percent-
ages. Differences in categorical variables were analyzed
using chi-square test. Linear correlations among the var-
iables were assessed using Spearman’s linear correlation
coefficient. A p value of <0.05 was considered statistically
significant. Statistical analysis was performed using an
IBM computer and PASW software, version 18.0 (SPSS,
Inc., Chicago, USA).
Results
A total of 25 SP-MS patients, including 14 females
(56 %) and 11 males (44 %) with a mean age of 38.92 ±
11.28 years participated in the study. The mean disease
duration was 8.70 ± 5.30 years (Table 1). MRI of the pa-
tients demonstrated diffuse hyper intense lesions in the
brain and also spine involvement.
Of the 25 patients, 2 (8 %) have a normal SPECT
and 23 (92 %) have abnormal brain perfusion SPECT
studies. Brain perfusion SPECT in the abnormal group
included: 2 (8 %), 20 (80 %) and 1 (4 %), which showed
mild, moderate and severe perfusion scans, respectively
(Table 1).
In total, 16 patients were treated with HBOT (Table 2).
The brain perfusion scans that were obtained before and
after therapy showed a significant improvement in perfu-
sion scan results (P <0.05) (Figs. 1, 2, 3 and 4). However,
the HBOT did not demonstrate a significant improve-
ment in clinical subjective and objective evaluation of
the patients (P >0.05).
Obtained hypoperfusion regions in a patient with
multiple sclerosis compared with healthy control group
through SPM was mapped on T1 MRI transaxial images
(Fig. 5).
The study showed a significant association of severity
of perfusion impairment with disease duration and also
with EDSS (P <0.05).
Table 1 Patients’ characteristics of all included patients
Variable Total patients (25)
Age (year) 38 (range: 21–58)
Male/Female 11/14
Disease duration (year) 8.70 ± 5.30 (range:1–21)
EDSS (range) 4 (2–8)
Abnormal perfusion (% of all)
(mild/moderate/severe)
23 (92) (2/20/1)
Number of patients who
underwent O2 therapy (% of all)
16 (64)
O2 therapy session 20
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The time interval between the two before- and after-
treatment SPECT examinations was 30–180 days (mean
time interval, 64.43 ± 38.66 days).
The SPM results table plus its corresponding glass
brain of a patient with two subsequent HBOT sessions
were presented. There are three follow up results indicat-
ing therapy was effective and also based on the obtained
figures the regions with significantly reduced perfusion
became smaller and smaller and finally in the last scan
there was no significant hypoperfused region where the
results are in alignment with the visual physician assess-
ment (Tables 3 and 4) (Fig. 6).
A group semi-quantitative analysis using SPM was per-
formed which clearly showed a significant hypoperfusion
in the right medial orbitofrontal cortex (Table 5, Fig. 7).
Discussion
In this study, we investigated cerebral perfusion by
SPECT in SP-MS, and evaluated the effects of HBOT in
the CBF of these patients. Our study revealed abnormal
cerebral perfusion in 92 % of SP-MS patients and for the
first time showed that cerebral perfusion significantly
improved after HBOT. In addition, it depicted a remark-
able association between brain perfusion defects and
clinical status. Such findings were also seen on voxel-
based analysis of whole-brain data using SPM analysis.
Statistical parametric mapping is a neuroimaging
analysis tool which evaluates the statistical significance
of cerebral blood flow (CBF) alterations on a voxel by
voxel basis, which is more reliable than conventional
ROI analysis due to the inherent subjectivity of these
Table 2 Characteristics of MS patients who underwent hyperbaric oxygen therapy (HBOT)
Patient no. EDSS Interval time (day) Disease duration (year) Pre-treatment scan Post treatment scan
1 4 90 9 Moderate bifrontoparital Mild bifrontoparital
2 5 30 8 Severe Rt hemisphere Mild Rt hemisphere
3 3 30 4 Moderate diffuse cortical Mild diffuse cortical
4 6 50 10 Mild Rt hemisphere Normal
5 2 240 7 Moderate Rt hemisphere Moderate Rt hemisphere
6 2 52 2 Normal Normal
7 3 60 6 Moderate diffuse (L > R) Moderate diffuse (L > R)
8 3 32 2 Moderate Rt temporal Moderate Rt temporal
9 3 50 3 Moderate bi temporal Mild bitemporal
10 6 70 13 Moderate Rt posterior temporal Normal
11 6 65 11 Moderate bi temporoparital and caudate nucleus Normal
12 8 26 7 Moderate Rt occipital Moderate Rt occipital
13 3 60 7 Moderate Rt occipital Moderate Rt occipital
14 8 60 1 Moderate Lt occipital and putamen Mild Lt occipital and putamen
15 4 40 5 Moderate bifrontoparital and diffuse subcortical Normal
16 2 60 5 Moderate Lt occipital Normal
EDSS expanded disability status scale
Fig. 1 The percent of MS patients based on severity of hypoperfusion in pre-treatment (left side) and post-treatment (right side) on brain perfusion
99mTc-ECD SPECT images
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methods [28]. SPM was used to identify regions with
decreased CBF in each patient compared to the control
group [15].
Perfusion studies of MS have different results that
may be due to various perfusion measurement tech-
niques and stages of disease [6, 7]. In our previous
study, we investigated cerebral perfusion in early RR-
MS patients with mild or no disability, which deter-
mined normal cerebral perfusion in all patients [7].
Other studies showed different brain perfusion in MS
patients particularly in those with a progressive type
of disease [6].
By using an arterial spin labeling sequence in early
RR-MS patients, Debernard et al. found reduced perfu-
sion in deep GM and different cortical regions, including
lingual gyrus, intracalcarine, insular and operculum
cortex, temporal, parietal, frontal and occipital cortical
regions [29]. In another study, Rashid et al. by arterial
spin labeling, found hypoperfusion in several cortical
regions of patients with primary and SP-MS but not in
patients with RR-MS [30].
Ota et al. assessed the CBF of MS patients by arterial
spin labeling and revealed reduced CBF in the bilateral
thalami and right frontal region of the patients compared
Fig. 2 Pre-treatment (upper rows) and post-treatment (lower rows) SPECT images of a 58-year-old MS patient. There is a moderate hypoperfusion
in the posterior right temporal cortex on pretreatment 99mTc-ECD brain perfusion SPECT, which is normalized after hyperbaric oxygen therapy
(HBOT). The EDSS of the patient was 6.00 and her disease duration was about 13 years
Fig. 3 Pre-treatment (upper rows) and post-treatment (lower rows) SPECT images of a 45-year-old MS patient. There is moderate hypoperfusion in
the temporo-parietal regions and caudate nucleus (R>L) on pretreatment 99mTc-ECD brain perfusion SPECT, which is almost completely normalized
after hyperbaric oxygen therapy (HBOT). The left columns indicate transverse 99mTc-ECD SPECT images; the middle columns indicate coronal
99mTc-ECD SPECT images; and the right columns indicate sagittal 99mTc-ECD SPECT images. The EDSS of the patient was 6.00 and her disease
duration was about 11 years
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to the healthy volunteers [31]. Lyke et al. evaluated the
CBF of MS patients by brain SPECT and showed that CBF
was significantly reduced in the patients—particularly
in those with the progressive type of MS [6]. Adhya
et al. by using dynamic susceptibility contrast perfu-
sion MRI, reported that the CBF was significantly de-
creased in all normal-appearing white matter (NAWM)
regions in the MS patients, and that PP-MS patients
showed a significantly lower CBF compared to RR-MS
patients [32]. Law et al. determined that the NAWM
region of patients with RR-MS had significantly lower
CBF compared with the NAWM of control group [4].
Several direct and indirect mechanisms might have
contributed to the change in cerebral perfusion of MS
patients. The reduction of white matter perfusion may
occur following a decrease in tissue metabolism, or it
may be due to a primary vascular pathology that may
impair cerebral flow [29]. Lower metabolic activity of the
cerebral region secondary to neuronal loss (due to the
demyelination process) might decrease CBF. Neuronal
loss may originate from hypoperfusion, iron deposition,
demyelination, or Wallerian degeneration [33]. Neuronal
metabolic dysfunction secondary to inflammation with
consequent mitochondrial dysfunction may decrease the
demand for blood supply and eventually brain perfusion
[29]. Axonal transection in the demyelination lesion of the
white matter could result in anterograde and retrograde
degeneration of axons that are associated with neuronal
dysfunction and will consequently decrease GM perfusion
[33]. An abnormal cerebral vasculature is another possible
mechanism of the GM hypoperfusion [29]. The inflamma-
tory process may cause microvascular damage by several
mechanisms. Reaction of cytotoxic T cells with the specific
antigen on endothelial surface may start a clotting cascade
Fig. 4 Pre-treatment (upper rows) and post-treatment (lower rows) SPECT images of a 51-year-old MS patient. There is mild to moderate
hypoperfusion through the fronto- parietal cortices bilaterally and sub-cortical structures on pretreatment 99mTc-ECD brain perfusion SPECT,
which is almost completely normalized after hyperbaric oxygen therapy (HBOT). The upper rows indicate transverse 99mTc-ECD SPECT images;
the middle rows indicate sagittal 99mTc-ECD SPECT images; and the lower rows indicate coronal 99mTc-ECD SPECT images. The EDSS of the
patient was 4.00 and her disease duration was about 5 years
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that eventually results in thrombus formation. Similarly,
specific antibodies may react with their antigen on the
endothelial cells and result in vascular damage via com-
plement activation. Furthermore, inflammatory vascular
edema may interfere with vascular blood flow following
focal tissue swelling; whereas acute and chronic venous
obliterations may develop as a result of exudation of in-
flammatory cells and intravascular fibrin deposition [34].
In addition, obliterative vasculitis might cause chronic
ischemia resulting from modulation of the vascular tone
and the CBF [33, 35]. An increase in the calcium concen-
tration of extracts, neuronal and glial cells shown in MS
lesions may be associated with an increase in the tone of
blood vessels. Also, a high blood level of endothelin-1, a
vasoconstrictor compound, is seen in MS [29, 35]. An
abnormal brain cortical-subcortical circuit is considered
to be the other mechanism of decreasing brain perfusion
in MS patients, which theoretically may be caused by deep
GM lesions like the thalamus even by a small lesion that is
not obvious [31].
In addition, it revealed a noticeable association be-
tween brain perfusion abnormalities and clinical status.
In our previous study, we investigated cerebral perfusion
in early RR-MS patients with mild or no disability (EDSS
score <1) [6]. In contrast, current study depicted signifi-
cantly cerebral perfusion impairment in MS patients
with moderate to severe disability may indicate cerebral
perfusion defect increasing with worsening EDSS score.
In line with our findings, Lycke et al. [5] evaluated cere-
bral perfusion in 19 patients with MS and visualized low
cerebral perfusion in the frontal grey matter correlated
with neurological disability and low perfusion in frontal
grey and white matter correlated with impaired cognitive
functions. Up to now, clinical and magnetic resonance
Fig. 5 Shows the brain regions with reduced perfusion in one of the MS patients compared with the healthy control group. With a height
threshold of P <0.05 (corrected for multiple comparison, T = 7.18), there was significant hypoperfusion in different brain areas including right
anterior cingulate gyrus, right superior temporal gyrus, left fusiform gyrus, right insula, left inferior frontal gyrus, left anterior cingulate gyrus, left
middle temporal gyrus, right supplementary motor area, right lobule IV, V of cerebellar hemisphere, left putamen, left thalamus, left lobule VI of
cerebellar hemisphere, right hippocampus, right caudate nucleus. These regions are displayed on transaxial images. Hypoperfusion regions were
displayed according to a specified threshold (p <0.05, corrected, T = 7.182) image indicates distance (mm) from anterior commisure– posterior
commisure plane
Table 3 Brain regions with significantly reduced perfusion using statistical parametric mapping analysis, Height threshold, T = 7.26,
{p <0.05 (FWE)}
p (FWE-corr) T Z Coordinates x, y, z {mm} max. peak Brain area
0.009429 9.117918 4.899239 26, 46, −6 Right superior frontal gyrus, orbital part
0.021354 8.183681 4.672336 −0, −54, 34 Left precuneus
0.02832 7.874513 4.590642 −38, −10, −18 Medial temporal lobe
0.028749 7.858227 4.586238 −46, −8, −20 Left temporal lobe
0.03078 7.784257 4.566107 −40, −18, −24 Left inferior temporal gyrus
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imaging examinations considered as routine tools to pre-
dict disability progression and then appropriate manage-
ment in MS, however no single parameter is expected to
have sound prognostic significance due to complex
pathogenesis of MS. What’s more, no conventional MRI
procedures has shown strong correlation with long-term
disability progression in MS patients, while more devel-
oped MRI techniques are currently being investigated
with promising results in preclinical settings [35]. The
relation between EDSS score and perfusion defect sug-
gest that brain perfusion defect may be helpful param-
eter to monitor clinical disability and eventually disease
progression in MS patient and brain perfusion SPECT
can be complementary to other diagnostic modalities
such as MRI and clinical examinations in disease surveil-
lance and monitoring. We didn’t evaluated association
between MRI lesions and perfusion defect because be-
yond the scope of our study and should be considered in
follow up studies.
Based on the group analysis, right medial orbito
frontal cortex was obtained as the significant perfused
area among the multiple sclerosis patients, we offered
that if the study extended to more patients with MS we
may have more precise areas as defected regions. In
addition, the aforementioned region was demonstrated
on our prior studies that had an important role in status
of olfactory. It may amend to do a follow up study in
MS patients [33, 36].
Although our study didn’t show a significant clinical
benefit from HBOT on the MS patient, the treatment
significantly improved the patients’ cerebral perfusion.
Another study showed similar results in a clinical setting
Table 4 Brain regions with significantly reduced perfusion using statistical parametric mapping analysis, Height threshold, T = 7.26,
{p <0.05 (FWE)}
p (FWE-corr) T Z Coordinates x, y, z {mm} max. peak Brain area
0.02072 8.219753 4.681639 26, 46, −6 Right superior frontal gyrus, orbital part
0.026836 7.935467 4.607033 −36, −10, −20 Medial temporal lobe
Fig. 6 Brain Perfusion SPECT and statistical parametric mapping analysis of a MS patient underwent HBOT. First brain perfusion study of MS
woman patient showed moderate hypoperfusion of inferior temporal lobe on the right side (a). Second brain perfusion study 33 days after first
study and following first oxygen therapy showed mild and moderate hypoperfusion of inferior temporal lobe on the right side at first scan
(no significant change in visual analysis) (b). Third brain perfusion study 4.4 months after second study and following second oxygen therapy
showed rather normal radiotracer distribution through the cortical and subcortical regions (significant changes on visual analysis) (c). The upper
rows indicate transverse 99mTc-ECD SPECT images; the middle rows indicate sagittal 99mTc-ECD SPECT images; and the lower rows indicate
coronal 99mTc-ECD SPECT images
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[34]. In a small, randomized, placebo-controlled trial of
HBOT, Martin et al. showed a transient mild improve-
ment in CNS functions, including mobility, coordin-
ation, and bladder control, and a reduction in fatigability
that is associated with changes of two or more points on
the Kurtzke disability status scale [34]. A study by
Barnes et al. showed that HBOT in 120 patients with
chronic MS was not associated with improvement on
the Kurtzke disability status scale [37]. Kindwall et al.
didn’t show any benefit from HBOT in MS patients
compared to the control group, except for a temporary
improvement in bladder control which was reported by
some patients [38]. Furthermore, two other main studies
did not demonstrate a beneficiary from HBOT in MS
patients [9, 38].
The clinical imaging dissociation may originate from
the object that old lesions with severe tissue injury in a
specific region of the CNS, such as the brainstem and
spinal cord, are not affected by HBOT and consequently
are not beneficial from the treatment. However, to our
knowledge, no functional brain imaging research exists
addressing this question in MS subgroups.
The mechanism of the HBOT effect is uncertain. One
possibility is an immunosuppressive effect. Another pos-
sibility is that ischemic areas of perivenular plaques,
which come from an associated venous occlusion, are
transiently resolved by HBOT [8]. At the cellular level,
HBOT seems to ameliorate neuronal and glia cells’ mito-
chondrial function and eventually cellular metabolism,
reduces oxidative stress, augments neurotrophins and ni-
tric oxide concentrations, and up-regulates axon guidance
agents. The treatment may also induce neurogenesis and
reduce apoptosis [38]. Another possible mechanism is that
hyperoxia acts as a neuronal stimulant [39]. Hyperoxia
decreases membrane conductance and affects ion channel
closures, presumably decreasing outward (K) and/or in-
ward (Cl) currents that eventually causing depolarization
and stimulated to fire rate [39].
All of the mechanisms can promote neuronal activity
and metabolism, and eventually increase cerebral perfusion
Table 5 Brain regions with significantly reduced perfusion in multiple sclerosis patients (5 patients) compared with control subjects,
Height threshold, T = 6.0291, {p <0.05 FWE}
p (FWEcorr) T Z Coordinates x, y, z {mm} max. peak Brain area
0.003843 7.936576 4.986516 18, 36, −8 Right medial orbitofrontal cortex
Fig. 7 Brain regions with significantly reduced perfusion (statistical parametric mapping) in patients Vs. control subjects (group analysis)
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[40–43]. However, there are ongoing studies on HBOT
with promising results at least based on imaging findings
indicating it will be a open argument in various neuro-
logical disorders [15, 16, 44, 45].
In summary, the data may depict diminished cerebral
perfusion in SP-MS patients with a moderate to severe
disability score and its remarkable association with clin-
ical parameters. Because of its accessibility, rather low
price, practical ease, and possibility to acquire objective
quantitative information, brain perfusion SPECT can be
complementary to other diagnostic modalities in dis-
ease surveillance and monitoring, even though add-
itional neurophysiological and imaging investigations
are needed. Besides, it might depict the effect of hyper-
baric oxygen therapy in the improvement of cerebral
perfusion in MS patients but not in clinical outcome.
However, it could keep the physiological debate open
in which this approach may have some value. The lit-
erature on this important issue is scarce, and follow
up studies are required to assess these preliminary
results.
Finally, it should be mentioned that the current study
has a number of limitations. One of the most important
limitations is the relatively low number of participants;
however, it was quite homogenous in terms of the
disease severity of patients. Another limitation of the
study is that we didn’t assess the possible association
of the cognitive status of MS patients with the im-
provement in brain perfusion following HBOT mostly
due to retrospective nature of this study. Further-
more, most brain perfusion studies showed improve-
ment following HBOT without a substantial effect on
clinical subjective and objective evaluation in the
short-term follow up. Extended monitoring in a more
prolonged time course should be taken into account
in future studies.
Conclusion
This study demonstrated decreased cerebral perfusion in
SP-MS subjects with a moderate to severe disability
score and its association with clinical parameters. Because
of its accessibility, rather low price, practical ease, and
being objective quantitative data, brain perfusion SPECT
could be complementing to other diagnostic modalities
such as MRI and clinical examinations in disease
surveillance and monitoring, even though additional
neurophysiological and imaging investigations are highly
required.
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